crf1

CP 316311 is a specific CRF1 receptor antagonist with potential antidepressant activity and may be used in the study of depression.

Pexacerfont (BMS-562086) is a selective antagonist of the corticotropin-releasing factor receptor (IC50: 6.1±0.6 nM for the human CRF1 receptor).

R121919 (NBI30775) is a potent small molecule antagonist of the adrenocorticotropic hormone-releasing factor receptor 1 (CRF1), demonstrating antidepressant and anxiolytic activity, and inhibiting the CRF1 receptor, CRF2 receptor, and CRF-binding proteins.

Tildacerfont is an antagonist of CRF1 and reduces the levels of adrenocorticotropic hormone and adrenal androgen. Tildacerfont can be used in studies about congenital adrenal hyperplasia.

Urocortin (rat) acetate is an agonist of endogenous CRFR with Kis of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF2α and mouse CRF2β, respectively. Urocortin (rat) acetate is a neuropeptide.

α-helical CRF 9-41 acetate is a competitive antagonist of CRF2 (KB = 100 nM) and a partial agonist of CRF1 (EC50 = 140 nM).

Emicerfont is an antagonist of the corticotropin-releasing factor type 1 receptor (IC50: 66 nM).

CRF1 Receptor Antagonist-1 (Compound 2), a CRF1 receptor antagonist, is utilized in research pertaining to congenital adrenal hyperplasia (CAH) [1].

Crinecerfont (SSR-125543) is a selective antagonist of corticotropin-releasing factor 1 receptor (CRF1) and can be used in studies about Classic congenital adrenal hyperplasia.

Urotensin I acetate, a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF2α receptors in CHO cells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF2α and mCRF2β receptors, respectively[1][2].

CP 154526 hydrochloride is a blood-brain barrier-penetrant, selective CRF1 (corticotropin-releasing factor receptor 1) antagonist (Ki = 2.7 nM) exhibiting thousands of times greater selectivity for CRF1 over CRF2, with anxiolytic and antidepressant activities.

corticotropin-releasing factor1 (CRF1) receptor antagonist

Verucerfont (NBI77860) is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) .

Urocortin, human (Human urocortin I) is a 40 amino acid peptide which is closely related to corticotrophin-releasing factor (CRF).

K41498 acetate, an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF2α- and hCRF2β-expressing cells. K41498 acetate is a potent and highly selective antagonist CRF2 receptor with Ki values of 0.66 nM, 0.62 nM and 425 nM for human CRF2α, CRF2β and CRF1 receptors respectively.

Dexrazoxane (ICRF-187) is an anticancer drug used to block mitosis and arrest dividing cells. It is an iron chelator and provides cardioprotection against anthracycline toxicity.

Razoxane is used as an antimitotic agent with immunosuppressive properties.

Cardioxane (ADR-529) is a cardio-protective drug.

Cyanabactin is a novel ABA receptor agonist. It preferentially activates Pyrabactin Resistance 1 (PYR1) with low nanomolar potency.

ICRF-193 is a DNA topoisomerase II inhibitor.

ICRF-196 is a Topoisomerase II Inhibitor and antineoplastic agent.

NVS-CRF38 is an antagonist of corticotropin-releasing factor receptor 1 (CRF1).

Crinecerfont tosylate is an effective oral CRF1 receptor antagonist. It is applicable to studies involving congenital adrenal hyperplasia (CAH).

AAG561 is a corticotropin-releasing factor receptor 1 (CRF1) antagonist. It is useful for researching potential emotional dysregulation associated with psychiatric disorders or mental illnesses.